HelixNano

What HelixNano does

HelixNano (legal name: Helix Nanotechnologies, Inc.) is a privately held biotechnology company headquartered at 5 Channel Center Street, Suite 600, Boston, MA that is developing an AI-enabled drug design platform built on nucleic acid technologies. The company's stated thesis is the creation of "self-designing" therapeutics that would improve with each patient treatment and could, in principle, require only a single administration — a vision that would, if achieved, mark a structural departure from conventional small-molecule and biologic drug paradigms. Operationally the company is in stealth: the website displays only a tagline ("What if a drug could design itself?") and a "More soon" placeholder, no named product candidates or pipeline programs are publicly disclosed, no patents or IP filings are listed, and no pricing model or revenue mechanics are described.

The company is led by co-founder and CEO Hannu Rajaniemi and supported by a four-member advisory board spanning nucleic acid technologies (George M. Church, Harvard Medical School / Wyss Institute), immuno-oncology (Fred Ramsdell, Parker Institute for Cancer Immunotherapy / Sonoma Biotherapeutics / Novo Nordisk), strategy (Ron Martell, Jasper Therapeutics / Indapta Therapeutics / Genentech), and cancer genomics (Adam Bass, Novartis NIBR / Columbia / Dana-Farber). Marianna Keaveney leads preclinical formulations and in vivo testing. The company is a Y Combinator alumnus (2017) and has raised approximately $48 million in disclosed financings across more than 20 rounds between 2017 and 2024, with the largest being a $45M round in March 2022 led by Milano Investment Partners SGR. With 1–10 employees and no disclosed revenue, HelixNano currently functions as a capital-backed, AI-native preclinical R&D effort rather than a commercial enterprise.

Name

HelixNano

Legal name

Helix Nanotechnologies, Inc.

Website

https://helixnano.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

HelixNano is a Boston-based, privately held biotechnology company developing an AI-enabled nucleic acid drug design platform aimed at creating therapeutics that improve with each patient treatment. The company operates in stealth with no commercial products, and is backed by Y Combinator and venture investors including Milano Investment Partners.

Ownership category

akta.pro rank

Product category

AI Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• AI drug discovery
• Nucleic acid therapeutics
• Genetic disease treatments
• Biotech drug development
• Computational drug design

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

HelixNano is a biotechnology company developing an AI-enabled drug development platform that designs nucleic-acid-based therapeutics targeting genetic diseases. The company is working toward self-designing drugs intended to improve with each patient and act as single-dose cures for genetic conditions. The company is currently in pre-commercial/stealth mode with no marketed products.

Product overview

HelixNano is a biotechnology company developing an AI-enabled drug development platform. Based on the company tagline, the platform aims to create self-designing drugs that improve with each patient treatment and may potentially require only a single administration. The company is in stealth mode with minimal public-facing product information; no specific named products or modules have been publicly disclosed.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights3 records

Direct peers

• Insitro: Machine-learning-driven drug discovery company operating an AI-bio platform to design therapeutics against genetically validated targets. Closely comparable to HelixNano in core thesis (AI to redesign small molecules and biologics) though Insitro is further along in partnerships and pipeline depth.
• Recursion Pharmaceuticals: AI-native biotech combining high-throughput biology with machine learning to discover and develop therapeutics across multiple indications. Comparable to HelixNano in platform-based AI drug discovery, with a more mature pipeline and public-market validation.
• Generate Biomedicines: Generative AI platform that designs novel protein therapeutics from scratch. Comparable to HelixNano's generative AI drug-design thesis, but applied to protein rather than nucleic acid modalities.
• Strand Therapeutics: Synthetic biology company programming self-replicating mRNA therapeutics with logic-gated gene expression. The most directly comparable peer: shares both the nucleic acid modality and the vision of smart/programmable drugs with embedded computation.
• Inceptive: AI-driven RNA biology company designing RNA-based medicines with deep learning. Closely comparable to HelixNano in combining AI with nucleic acid therapeutic design, with comparable stealth-stage posture.

Emerging players

• Cradle Bio: AI platform for protein engineering and biologics design, leveraging generative models to accelerate wet-lab iteration. Comparable platform approach to HelixNano's AI drug-design intent.
• AbCellera: AI-enabled antibody discovery platform partnering with pharma to generate therapeutic candidates. Comparable in AI-augmented biologics discovery, though focused on antibodies rather than nucleic acid therapeutics.

Broad incumbents

• Beam Therapeutics: Clinical-stage biotechnology company developing precision genetic medicines using base-editing nucleic acid technology. Comparable modality (engineered nucleic acids for genetic disease), though far more advanced and capitalized.
• Ginkgo Bioworks: Cell engineering and synthetic biology platform serving multiple end markets including therapeutics. Comparable in synthetic biology tooling but operates a much broader, codeable-biology platform rather than a focused therapeutic pipeline.
• Moderna: Commercial-stage mRNA therapeutics company with deep nucleic acid platform capabilities. Comparable in nucleic acid modality for genetic and infectious diseases, but operates at vastly greater scale and clinical maturity.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/HelixNano
• LinkedInlinkedin.com/company/4992142

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds24 records

Investors27 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HelixNano